Atorvastatin lost its primary patent on November 30, 2011. What followed was the most studied loss-of-exclusivity response in pharmaceutical history. […]
1. Why Patent Portfolio Management Determines Market Survival Pharmaceutical patent portfolio management is not a legal overhead function. It is
Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams Read Post »
Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making
Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the
1. What the 505(b)(2) Pathway Actually Is (and What It Isn’t) The 505(b)(2) New Drug Application (NDA) is a hybrid
505(b)(2) Mastery: The Complete IP Strategy Guide for Drug Lifecycle Extension Read Post »
A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Why Most Generic Drug Strategies
What Branded Generics Actually Are — and Why the Definition Matters for IP Teams The pharmaceutical industry uses ‘branded generic’
Branded Generics ROI: The Complete IP, Pricing, and Market Strategy Playbook Read Post »
Drug repurposing has a dirty secret. For every sildenafil-to-Viagra success story, there are dozens of ventures that got five years
FTO Analysis for Drug Repurposing: The Complete IP Strategy Guide Read Post »
Patent cliffs get all the attention. Divisional patents do the real work. When a blockbuster drug faces loss of exclusivity,
Sign in or create a free account to read this DrugPatentWatch article
